Becton, Dickinson and Company (NYSE:BDX) Holdings Raised by Beese Fulmer Investment Management Inc.

Beese Fulmer Investment Management Inc. lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,735 shares of the medical instruments supplier’s stock after purchasing an additional 713 shares during the period. Becton, Dickinson and accounts for 1.2% of Beese Fulmer Investment Management Inc.’s investment portfolio, making the stock its 28th biggest holding. Beese Fulmer Investment Management Inc.’s holdings in Becton, Dickinson and were worth $5,216,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of BDX. Guardian Life Insurance Co. of America grew its stake in Becton, Dickinson and by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock valued at $150,000 after buying an additional 6 shares in the last quarter. Wellington Shields & Co. LLC grew its stake in Becton, Dickinson and by 0.3% in the 1st quarter. Wellington Shields & Co. LLC now owns 2,534 shares of the medical instruments supplier’s stock valued at $465,000 after buying an additional 8 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in Becton, Dickinson and by 1.4% in the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares in the last quarter. Northstar Group Inc. grew its stake in Becton, Dickinson and by 0.3% in the 2nd quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock valued at $584,000 after buying an additional 9 shares in the last quarter. Finally, North Star Investment Management Corp. boosted its holdings in Becton, Dickinson and by 3.4% in the 1st quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after purchasing an additional 18 shares during the period. Institutional investors own 87.43% of the company’s stock.

In other Becton, Dickinson and news, EVP Ribo Alberto Mas sold 7,463 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $201.41, for a total value of $1,503,122.83. Following the transaction, the executive vice president now directly owns 29,323 shares in the company, valued at $5,905,945.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at $2,538,890.01. The disclosure for this sale can be found here. In the last ninety days, insiders sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Becton, Dickinson and Company (NYSE:BDX) Holdings Raised by Beese Fulmer Investment Management Inc.” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/09/17/beese-fulmer-investment-management-inc-buys-713-shares-of-becton-dickinson-and-company-bdx.html.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 195.34 on Friday. The firm has a 50-day moving average of $199.43 and a 200-day moving average of $191.33. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63. The stock has a market cap of $44.45 billion, a PE ratio of 56.57 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business’s quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.35 earnings per share. On average, equities research analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.49%. Becton, Dickinson and’s dividend payout ratio (DPR) is 83.43%.

BDX has been the subject of several analyst reports. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and cut their price target for the company from $210.00 to $180.00 in a report on Friday, June 30th. Bank of America Corporation reissued a “buy” rating and issued a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday, July 17th. Finally, BidaskClub raised shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $196.93.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply